Subcortical 18F-AV-1451 binding patterns in progressive supranuclear palsy

Movement Disorders

Volumn 32, Issue 1, 2017, Pages 134-140

  Cho, Hanna ^a   Choi, Jae Yong ^a   Hwang, Mi Song ^a   Lee, Seung Ha ^a   Ryu, Young Hoon ^a   Lee, Myung Sik ^a   Lyoo, Chul Hyoung ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

18F AV 1451; Parkinson's disease; PET; Progressive supranuclear palsy; tau

Indexed keywords

FLORTAUCIPIR F 18; NEUROMELANIN; TAU PROTEIN; 7-(6-FLUOROPYRIDIN-3-YL)-5H-PYRIDO(4,3-B)INDOLE; CARBOLINE DERIVATIVE;

ADULT; AGED; ARTICLE; BRAIN REGION; CLINICAL ARTICLE; CONTROLLED STUDY; DENTATE NUCLEUS; DISEASE SEVERITY; FEMALE; GLOBUS PALLIDUS; HUMAN; MALE; MINI MENTAL STATE EXAMINATION; MOTOR DYSFUNCTION; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PUTAMEN; SUBCORTEX; SUBSTANTIA NIGRA; SUBTHALAMIC NUCLEUS; UNIFIED PARKINSON DISEASE RATING SCALE; CEREBELLUM NUCLEUS; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED; PROCEDURES;

AGED; CARBOLINES; CEREBELLAR NUCLEI; FEMALE; GLOBUS PALLIDUS; HUMANS; MALE; MIDDLE AGED; PARKINSON DISEASE; POSITRON-EMISSION TOMOGRAPHY; PUTAMEN; SUBTHALAMIC NUCLEUS; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS;

EID: 84996538238     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26844     Document Type: Article

References (26)

1. Williams DR, Lees AJ. Progressive supranuclear palsy: clinicopathological concepts and diagnostic challenges. Lancet Neurol 2009;8:270–279.
2. Williams DR, Holton JL, Strand C, et al. Pathological tau burden and distribution distinguishes progressive supranuclear palsy-parkinsonism from Richardson's syndrome. Brain 2007;130:1566–1576.
3. Kepe V, Bordelon Y, Boxer A, et al. PET imaging of neuropathology in tauopathies: progressive supranuclear palsy. J Alzheimers Dis 2013;36:145–153.
4. Villemagne VL, Fodero-Tavoletti MT, Masters CL, Rowe CC. Tau imaging: early progress and future directions. Lancet Neurol 2015;14:114–124.
5. Marquie M, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Ann Neurol 2015;78:787–800.
6. Sander K, Lashley T, Gami P, et al. Characterization of tau positron emission tomography tracer [18F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias [published online ahead of print 2016]. Alzheimers Dement.
7. Hammes J, Bischof GN, Giehl K, et al. Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy [published online ahead of print 2016]. Mov Disord.
8. Hansen AK, Knudsen K, Lillethorup TP, et al. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET. Brain 2016;139:2039–2049.
9. Rowe JB, Vázquez Rodríguez P, Hong YT, et al. [18F]AV-1451 PET imaging of tau in progressive supranuclear palsy and Alzheimer's disease [abstract]. Mov Disord 2016;31(suppl 2);S375.
10. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord 2015;30:1591–1601.
11. Litvan I, Agid Y, Jankovic J, et al. Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology 1996;46:922–930.
12. Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain 2007;130:1552–1565.
13. Cho H, Choi JY, Hwang MS, et al. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology 2016;87:375–383.
14. Desikan RS, Segonne F, Fischl B, et al. An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest. Neuroimage 2006;31:968–980.
15. Fischl B, Salat DH, Busa E, et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002;33:341–355.
16. Fischl B, van der Kouwe A, Destrieux C, et al. Automatically parcellating the human cerebral cortex. Cereb Cortex 2004;14:11–22.
17. Kim JS, Cho H, Choi JY, et al. Feasibility of computed tomography-guided methods for spatial normalization of dopamine transporter positron emission tomography image. PLoS ONE 2015;10:e0132585.
18. Keuken MC, Bazin PL, Crown L, et al. Quantifying inter-individual anatomical variability in the subcortex using 7 T structural MRI. Neuroimage 2014;94:40–46.
19. Ashburner J. A fast diffeomorphic image registration algorithm. Neuroimage 2007;38:95–113.
20. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc B 1995;57:289–300.
21. Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005;128:1247–1258.
22. Wills J, Jones J, Haggerty T, Duka V, Joyce JN, Sidhu A. Elevated tauopathy and alpha-synuclein pathology in postmortem Parkinson's disease brains with and without dementia. Exp Neurol 2010;225:210–218.
23. Compta Y, Parkkinen L, O'Sullivan SS, et al. Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important? Brain 2011;134:1493–1505.
24. Braak H, Braak E. Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 1991;82:239–259.
25. Cho H, Choi JY, Hwang MS, et al. In vivo cortical spreading pattern of tau and amyloid in the Alzheimer disease spectrum. Ann Neurol 2016;80:247–258.
26. Ohtsuka C, Sasaki M, Konno K, et al. Differentiation of early-stage parkinsonisms using neuromelanin-sensitive magnetic resonance imaging. Parkinsonism Relat Disord 2014;20:755–760.